Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14033476 | 1.00 | AR (0.59) | ARCTSBLMNAALDH1A1NPSR1 | |
| SCHEMBL4048739 | 0.93 | AR (0.63) | ARCTSBLMNAALDH1A1MAPT | |
| SCHEMBL4038981 | 0.93 | AR (0.63) | ARCTSBLMNAALDH1A1MAPT | |
| SCHEMBL4042740 | 0.93 | AR (0.63) | ARCTSBLMNAALDH1A1MAPT | |
| SCHEMBL4219668 | 0.91 | AR (0.57) | ARCTSBLMNAALDH1A1MAPT | |
| SCHEMBL6376932 | 0.91 | AR (0.57) | ARCTSBLMNAALDH1A1MAPT | |
| SCHEMBL6212517 | 0.91 | AR (0.57) | ARCTSBLMNAALDH1A1MAPT | |
| SCHEMBL6492936 | 0.87 | AR (0.77) | ARCTSBALDH1A1 | |
| SCHEMBL5097882 | 0.87 | AR (0.57) | ARALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL5088693 | 0.87 | AR (0.57) | ARCTSBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| EP-1299385-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2002000653-A2 | FUSED CYCLIC COMPOUNDS AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-7432267-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMAPNY (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | NR2C2, NR0B2, NR0B1 | AR 32/4885CTSB 4693/4885LMNA 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.